How did Sanofi win over Bioverativ? It upped its bid—and called on activist investor Alex Denner

To snag Bioverativ in an $11.6 billion deal, Sanofi first played it cool—and then bypassed management to make a play with top investor Alex Denner. The result? $85 million for Bioverativ chief John Cox, $122 million for Denner and a projected 5% hike to Sanofi's 2018 earnings.Original Article